Pharmaceuticals can indirectly regulate remodeling while treating various diseases, or they can be designed to target mechanisms in the bone remodeling cycle intentionally. Glucocorticoids are antiinflammatory agents that are used broadly but have negative effects on bone health by decreasing osteoblast and osteocyte populations and increasing osteoclast survival . Despite this, they are often used to reduce chronic inflammation in rheumatoid arthritis that can otherwise lead to osteoporosis. Teriparatide, a PTH analog that has anabolic effects on the bone, has several proposed mechanisms for its action . Since teriparatide requires expensive daily injections, it is used mainly for severe osteoporosis or those who need to use glucocorticoids long-term for other conditions .